As part of PDA’s ongoing commitment to the future of the pharmaceutical industry, the Program Planning Committee would like to warmly invite you to join us for the 2021 PDA Advanced Therapy Medicinal Products (ATMP) Conference on 26-27 October.
The aim of this 2-day event is to support all stakeholders that are involved in the development and commercialization of novel and effective cell and gene and tissue therapies.
This year’s theme of Clearing the Hurdles and Winning the Race to Save Lives puts a spotlight on solutions rather than strictly the challenges associated with cell-based medicines. This year we have added a view from the other side of ATMP manufacturing. Hear from medical experts who are on the frontline and how they navigate the various challenges and roadblocks. We also added a hot topic session on hiring and job retention to help understand what are the motivating factors of trained employees for staying or leaving.
The agenda includes sessions on both early and late product lifecycle management with an emphasis on risk assessment and tech transfer, end-to-end CM&C and its vital role in safeguarding product quality and process consistency, the question of investing internally or externally to meet manufacturing capacity, regulatory updates and what needs to improve to get more life-saving products from clinical trials to commercialization, and lessons learned from the pandemic on supply chain management.
The conference will be a Virtual Event. The live plenary sessions including Q&A will provide engaging discussions.
Lori Daane, bioMérieux – Chair
Dayue Chen, Genentech/Roche
Josh Eaton, PDA
Irving Ford, Bristol-Myers Squibb
David Geoghegan, Tmunity
Katherine Giacoletti, Merck
Peter Makowenskyj, G-CON
Darius Pillsbury, ValSource
MaryEllen Usarzewicz, Bristol-Myers Squibb
The Scientific Program Planning Committee